Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Volume Increase – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw an uptick in trading volume on Friday . 20,050 shares traded hands during mid-day trading, an increase of 358% from the previous session’s volume of 4,378 shares.The stock last traded at $46.25 and had previously closed at $46.93.

Wall Street Analyst Weigh In

Several research firms recently commented on ZLDPF. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Three analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Performance

The company has a market cap of $3.24 billion, a PE ratio of 3.34 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57. The stock’s 50-day simple moving average is $51.76 and its 200 day simple moving average is $66.22.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The company had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. As a group, equities analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.